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CLINICAL TRIALS AND OBSERVATIONS
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In light-chain (AL) amyloidosis, progno-
sis is dictated by cardiac dysfunction.
N-terminal natriuretic peptide type B
(NT-proBNP) and cardiac troponins (cTn)
are used to assess the severity of cardiac
damage. We evaluated the prognostic rel-
evance of a high-sensitivity (hs) cTnT
assay, NT-proBNP, and cardiac troponin I
in 171 consecutive patients with AL amy-
loidosis at presentation and 6 months
after treatment. Response and progres-
sion of NT-proBNP were defined as more
than 30% and more than 300 ng/L
changes. All 3 markers predicted sur-
vival, but the best multivariable model
included hs-cTnT. The hs-cTnT prognos-
tic cutoff was 77 ng/L (median survival
10.6 months for patients with hs-cTnT
above the cutoff). After treatment, re-
sponse and progression of NT-proBNP
and a more than 75% increase of hs-cTnT
were independent prognostic determi-
nant. In AL amyloidosis, hs-cTnT is the
best baseline prognostic marker. Therapy
should be aimed at preventing progres-
sion of cardiac biomarkers, whereas
NT-proBNP response confers an addi-
tional survival benefit. (Blood. 2010;
116(18):3426-3430)
Introduction
In light-chain (AL) amyloidosis, a hematologic malignancy causes
multiorgan dysfunction, posing unique challenges to the hematolo-
gist.1 Organ damage increases the susceptibility to treatment
toxicity, whereas outcome depends on the ability to rapidly restore
organ function. Thus, there is the need of accurate markers for risk
stratification and organ response, to guide the choice of therapy and
assess its efficacy.2 The most important prognostic determinant in
AL amyloidosis is heart dysfunction, and its severity is best
assessed by the cardiac biomarkers N-terminal natriuretic peptide
type B (NT-proBNP) and cardiac troponins (cTn).3,4 The combina-
tion of these biomarkers allows prognostic stratification.5 More-
over, the reduction of NT-proBNP is associated with hematologic
response and prolonged survival.6
Recently, a new generation of high-sensitivity (hs) assays for
cTn has been developed to identify minimal cardiac damage in the
setting of acute coronary syndromes.7-9 Even slight elevations of
cTn are associated with poor outcome in ischemic heart disease,
indicating a role of hs-cTn also in prognostic stratification.8
Moreover, hs-cTn assays can detect circulating cTn also in patients
with heart failure and nonischemic heart disease.10
It has been recently proposed that studies of novel markers of
cardiovascular risk should report the degree to which they add to
the information already provided by standard markers, emphasiz-
ing that no single statistical measure provides all the information.11
In the present study, we investigated the added prognostic value of
high-sensitivity cardiac troponin T (hs-cTnT) in patients with AL
amyloidosis compared with established risk markers according to
these new criteria and its utility in determining the cardiac response
to therapy.
Methods
Patients
A total of 171 consecutive newly diagnosed patients with AL amyloidosis
enrolled between January 2004 and May 2008 were retrospectively
evaluated. All patients gave written informed consent according to the
Institutional Review Board guidelines and the Declaration of Helsinki. The
Institutional Review Board of the Fondazione Istituto di Ricovero e Cura a
Carattere Scientifico Policlinico San Matteo approved the storage and use
of biologic samples and the use of patients’ clinical data for research
purposes. Organ involvement and response to therapy were defined
according to the 2005 consensus criteria.12 In particular, heart involvement
was defined as mean left ventricular wall (mLVW) thickness more than
12 mm at echocardiography in the absence of other potential causes of left
ventricular hypertrophy, and hematologic response as a more than 50%
decrease of involved (amyloidogenic) circulating free light chains (iFLCs).
In patients in whom baseline iFLCs were less than 100 mg/L and who had a
measurable more than 5 g/L serum monoclonal component, hematologic
response was defined as a more than 50% reduction of the monoclonal
component. Based on the biologic variability of NT-proBNP13,14 and on
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previous studies in AL amyloidosis,6,15 response and progression of
NT-proBNP were defined as changes both more than 30% and more than
300 ng/L. A baseline NT-proBNP more than or equal to 650 ng/L was
required for NT-proBNP response to be evaluable. Response to therapy was
assessed 6 months after treatment initiation. Patients were treated with oral
melphalan plus dexamethasone (109, 64%),16 cyclophosphamide, thalido-
mide, and dexamethasone (22, 13%),17 dexamethasone alone (17, 10%),18
autologous stem cell transplantation (18, 10%), and other treatments
(5, 3%). Four patients were not evaluable for response because they died
before 6 months.
Analytical methods
The hs-cTnT was measured on the Modular E instrument with a precommer-
cial immunoassay from Roche Diagnostics on frozen sera. The 99th centile
of hs-cTnT concentration in sera from 546 healthy volunteers is 14 ng/L
(95% confidence interval, 12.4-24.9 ng/L). The analytical performance of
the assay has been recently validated.19 Serum NT-proBNP and cardiac
troponin I (cTnI) were measured on fresh sera with an electrochemilumines-
cence sandwich immunoassay (Roche Diagnostics) and a chemilumines-
cence assay (Advia Centaur CP, Siemens Diagnostics), respectively. The
upper reference limits of NT-proBNP in men and women are, respectively,
88 ng/L and 153 ng/L in subjects younger than 50 years and 227 ng/L and
334 ng/L in persons 50 years of age and older. A serum cTnI more than
40 ng/mL indicates minimal myocardial lesion (99th centile of the reference
population as reported by the manufacturer).
Statistical analysis
Continuous data were described with median and range. Biomarkers were
dichotomized according to their upper reference limits, the prognostic
cutoffs previously reported for AL amyloidosis,5 or using receiver operator
characteristic (ROC) curve analysis to identify the best cutoffs for death at
12 months. For NT-proBNP, the reference limits vary with sex and age and
are very close to the prognostic cutoff proposed by Dispenzieri et al
(332 ng/L).5 Thus, we used the latter for the purpose of survival analysis.
The patients were stratified according to the Mayo Clinic staging system:
stage I patients had both NT-proBNP less than 332 ng/L and cTnI less than
100 ng/L, stage II patients had either NT-proBNP more than or equal to
332 ng/L or cTnI more than or equal to 100 ng/L, and stage III patients had
both NT-proBNP more than or equal to 332 ng/L and cTnI more than or
equal to 100 ng/L.5 Cox models were fitted to compute hazard ratios and
95% confidence intervals for death for a series of potential predictors. For
evaluating the role of responses at 6 months, time-dependent Cox models
were fitted. The proportional hazard assumption was tested and satisfied in
all cases. To measure model performance, the Harrell concordance (c)
statistic (for discrimination between cases with and without the outcome, ie,
death, equivalent to the area under the ROC curve), the shrinkage
coefficient for calibration (measuring the accuracy of the model, ie, the
agreement between observed outcome and prediction), and the Royston
explained variation (R2, ability to account for the variation in the outcome
observed in the population) were computed (for all, the higher, the better).
Model fit was graphically assessed by Snell residuals. Multivariable models
were used, including noncollinear predictors showing a P less than .01 at
univariable analysis. The final model based on dichotomized, rather than
continuous, predictors was preferred for its easier clinical use and better fit
to the data. To account for the possible effect of renal failure on the
concentration of the cardiac biomarkers, particularly NT-proBNP, and of
iFLC, all the Cox analyses were repeated after stratification for renal
function according to a 60 mL/min per 1.73 m2 estimated glomerular
filtration rate (eGFR) cutoff. The ability of changes in the cardiac
biomarkers to discriminate patients who died at 1 year after evaluation of
response was assessed by ROC analyses. Survival curves were plotted
according to Kaplan-Meier and differences in survival tested for statistical
significance by the log-rank test. Stata 11 (StataCorp) and MedCalc 11
(Medcal Softwarem) were used for computation.
Results
A total of 171 consecutive untreated patients with AL amyloidosis
were included in the study. The patients’ characteristics are
reported in Table 1. It is worth noting that no patient with heart
involvement had normal NT-proBNP, in agreement with the
reported 100% diagnostic sensitivity of this biomarker.3
Prognostication of survival at presentation
Fifty-six patients (33%) died. The median follow-up of living
patients was 49 months (range, 19-70 months). The cutoffs best
predicting death at 1 year were 77 ng/L for hs-cTnT (Figure 1),
70 ng/L for cTnI, 2736 ng/L for NT-proBNP, 125 mg/L for iFLC,
12 mm for mLVW, and 55% for ejection fraction. The Mayo Clinic
staging system based on NT-proBNP and cTnI divided the patient
population in 3 groups with significantly different survival (supple-
mental Figure 1A, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). The
39 patients with hs-cTnT more than 77 ng/L were distributed as
follows: 1 of 37 subjects (3%) in stage I, 10 of 103 (10%) in stage
II, and 28 of 31 (90%) in stage III. The survival of the 10 stage II
patients with elevated hs-cTnT was not significantly different from
that of stage III patients (supplemental Figure 1B). At Cox
univariable analysis, all the 3 cardiac biomarkers significantly
predicted mortality, as well as the echocardiographic variables and
the concentration of iFLC (Table 2).
Because the 3 cardiac biomarkers were highly correlated, they
could not be included in a single multivariable model. Thus, we
fitted 3 alternative models. The one including hs-cTnT (Table 2)
Table 1. Characteristics of 171 patients with AL amyloidosis
Variable n (%) Median (range)
Age, y — 64 (38-84)
Male sex 100 (58) —
Kidney involvement 127 (74) —
Heart involvement (mLVW thickness  12 mm) 119 (70) —
Peripheral nervous system involvement 40 (23) —
Liver involvement 30 (17) —
 1 organ involved 141 (82) —
iFLC  125 mg/L 89 (52) —
NYHA class  2 64 (37) —
EF  55% 52 (30) —
eGFR, mL/min per 1.73 m2 — 68 (9-136)
eGFR  60 mL/min per 1.73 m2 62 (36) —
hs-cTnT, ng/L — 31 (3-420)
hs-cTnT  14 ng/L 121 (71) —
hs-cTnT  77 ng/L 39 (23) —
cTnI, ng/L — 40 (0-85)
cTnI  40 ng/L 79 (46) —
cTnI  70 ng/L 40 (23) —
cTnI  100 ng/L 31 (18) —
NT-proBNP, ng/L — 2591 (25-35 563)
NT-proBNP  332 ng/L 134 (78) —
NT-proBNP  2736 ng/L 64 (37) —
Mayo Clinic stage I (NT-proBNP  332 ng/L
and cTnI  100 ng/L)
37 (22) —
Mayo Clinic stage II (NT-proBNP  332 ng/L
or cTnI  100 ng/L)
103 (60) —
Mayo Clinic stage III (NT-proBNP  332 ng/L
and cTnI  100 ng/L)
31 (18) —
— indicates not applicable; NYHA, New York Heart Association; and EF, ejection
fraction.
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turned out to be the model most accurately predicting the patients’
outcome because it showed better agreement between observed and
predicted deaths (shrinkage coefficient 0.91 for the model, includ-
ing hs-cTnT, compared with 0.82 and 0.81 for those, including
cTnI and NT-proBNP, respectively), and accounted for a greater
proportion of the observed deaths (Royston explained variation
0.41 for the hs-cTnT model, compared with 0.33 for the cTnI and
0.24 the NT-proBNP ones). This indicates that hs-cTnT is a more
powerful prognostic determinant than NT-proBNP and cTnI.
Stratification for eGFR, to account for the effect of renal failure on
the concentration of cardiac biomarkers, particularly NT-proBNP,
and of iFLC, did not significantly change the results (not shown).
The performance of the univariable and multivariable models is
reported in supplemental Table 1.
Prognostication of survival at the time of evaluation of
response to chemotherapy
Hematologic response was achieved in 92 of 167 evaluable
patients (55%), including 38 (23%) complete remissions. Among
113 patients with baseline NT-proBNP more than or equal to
650 ng/L, 43 (38%) achieved NT-proBNP response. Of the
43 patients who achieved NT-proBNP response, 23 (53%) were in
complete remission, 18 (42%) were in partial hematologic re-
sponse, and 2 (5%) were nonresponders. Progression of NT-proBNP
was observed in 53 of 167 subjects (32%): 12 (23%) in partial
hematologic response and 41 (77%) nonresponders. Only one
patient, who obtained NT-proBNP response, achieved cardiac
response as assessed by echocardiography ( 2 mm mLVW thick-
ness reduction). A more than or equal to 2-mm increase in mLVW
thickness was observed in 4 patients, all of whom also had
NT-proBNP progression. A more than or equal to 20% decrease in
ejection fraction was observed in no patient.
Hematologic response significantly improved survival in the
overall patient population (median survival, 20 months vs not
reached, P  .001, Figure 2). Moreover, response and progression
of NT-proBNP could discriminate between 3 groups with signifi-
cantly different survival (Figure 3). Interestingly, also patients with
baseline hs-cTnT more than 77 ng/L significantly benefited from
hematologic (median, 3 months vs not reached, P  .002) and
NT-proBNP (median survival, 4 months vs not reached, P  .001)
response. However, among the 53 patients in whom NT-proBNP
progressed, partial hematologic response to treatment, which was
observed in 12 cases (23%), did not induce a significant survival
benefit (median, 8 vs 13 months, P  .34).
The ROC analyses based on death 1 year after evaluation of
response showed that percentage and absolute changes in
NT-proBNP better discriminated patients who died than changes in
Figure 1. Survival from diagnosis of 171 patients according to hs-cTnT
concentration at presentation. Median survival 10.6 months versus not reached,
P  .001.
Table 2. Cox analysis of survival
Variable HR (95% CI) P
Univariable analysis
Age 1.02 (0.99-1.04) .203
Male sex 1.39 (0.82-2.33) .219
ln(iFLC) 1.22 (1.02-1.46) .024
iFLC  125 mg/L 2.00 (1.19-3.37) .009
NYHA class  2 3.05 (1.83-5.06)  .001
mLVW thickness 1.14 (1.06-1.22) .001
mLVW thickness  12 mm 2.84 (1.44-5.59) .003
EF 0.96 (0.93-0.98) .001
EF  55% 1.62 (0.97-2.70) .064
ln(cTnI) 1.59 (1.26-2.01)  .001
cTnI  40 ng/L (url) 2.85 (1.55-5.24) .001
cTnI  70 ng/L 3.90 (2.16-7.05)  .001
cTnI  100 ng/L 4.64 (2.51-8.58)  .001
ln(NT-proBNP) 1.42 (1.20-1.68)  .001
NT-proBNP  332 ng/L 4.06 (1.63-10.14) .003
NT-proBNP  2736 ng/L 2.63 (1.60-4.34)  .001
ln(hs-cTnT) 1.78 (1.40-2.27)  .001
hs-cTnT  14 ng/L (url) 2.71 (1.37-5.34) .004
hs-cTnT  77 ng/L 4.33 (2.61-7.18)  .001
Multivariable analysis of baseline variables
iFLC  125 mg/L 1.72 (1.01-2.91) .045
NYHA class  2 2.20 (1.23-3.95) .008
mLVW thickness  12 mm 1.36 (0.63-2.92) .428
EF  55% 1.01 (0.59-1.74) .967
hs-cTnT  77 ng/L 3.83 (2.82-6.41)  .001
Time-dependent multivariable analysis,
including baseline variables and
hematologic and NT-proBNP response
iFLC  125 mg/L 1.34 (0.75-2.41) .320
NYHA class  2 1.87 (1.02-3.43) .043
mLVW thickness  12 mm 1.60 (0.72-3.54) .245
hs-cTnT  77 ng/L 4.55 (2.54-8.16)  .001
NT-proBNP response 0.45 (0.18-1.10) .074
NT-proBNP progression 3.79 (1.84-8.00)  .001
hs-cTnT increase  75% 3.31 (1.81-6.04)  .001
Hematologic response 0.69 (0.35-1.37) .295
HR indicates hazard ratio; CI, confidence interval; NYHA, New York Heart
Association; EF, ejection fraction; and url, upper reference limit.
Figure 2. Survival from the time of evaluation of response of 167 patients
according to hematologic response to treatment. Median survival 20 months
versus not reached, P  .001.
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hs-cTnT, as assessed by comparison of the areas under the ROC
curves (0.79 vs 0.61 for percentage variation, P  .004, and 0.83 vs
0.68 for absolute changes, P  .012). The hs-cTnT cutoff best
predicting death after treatment was a more than 75% increase.
Such a remarkable increase was observed only in 14 patients, 12 of
whom (86%) also had an NT-proBNP progression. Eleven (79%)
of the 14 patients in whom hs-cTnT increased by more than 75%
died. Furthermore, a hs-cTnT increase more than 75% identified
a subset of patients with a trend toward a shorter survival among
those in whom NT-proBNP progressed (median, 8 vs 24 months,
P  .063).
Hematologic response to therapy, NT-proBNP response and
progression, and hs-cTnT progression, along with baseline vari-
ables were included in a time-dependent multivariable model
stratified for renal function to take into account the effect of
impaired renal function on the concentration of NT-proBNP and
iFLC. In this model, the presence of heart failure at presentation,
baseline hs-cTnT more than 77 ng/L, NT-proBNP progression, and
hs-cTnT increase more than 75% were all independent prognostic
determinants, and NT-proBNP response had borderline statistical
significance (Table 2). The prognostic significance of NT-proBNP
response was lower in the multivariable model without stratifica-
tion for renal function (not shown).
Discussion
The role of baseline measurement of high-sensitivity cardiac
troponin T
The present study showed that all 3 cardiac biomarkers tested are
indicators of prognosis in AL amyloidosis. At univariable analysis,
the cutoffs of NT-proBNP, cTnI, and hs-cTnT were significantly
associated with survival, and it was possible to fit 3 multivariable
models, each including one biomarker. This is in agreement with
previous observations that NT-proBNP and cTnI are useful in
prognosticating survival in AL amyloidosis. Nevertheless, statisti-
cal significance is not the only indicator of the performance of a
marker of prognosis,11 and in our study, cardiac TnT measured with
a high-sensitivity assay proved to be the best baseline prognostic
marker in AL amyloidosis, showing higher accuracy in predicting
the patients’ outcome compared with cTnI and NT-proBNP. Using
presenting hs-cTnT concentration as a single variable, it is possible
to easily identify 2 groups of patients with strikingly different
survival: 1 year after diagnosis 52% of patients with baseline
hs-cTnT more than 77 ng/L die, compared with only 9% of other
subjects. Moreover, the use of hs-cTnT may further refine the Mayo
Clinic staging system. In our study, the survival of the 10 stage II
patients with elevated hs-cTnT was not different from that of stage
III patients, indicating that hs-cTnT may reclassify a proportion of
Mayo Clinic stage II patients as high-risk subjects. However, given
the low number of such patients in the present series, this
observation needs confirmation from larger studies. Thus, hs-cTnT
could be a simple, although powerful, tool both for single subjects
risk assessment and for patient stratification in clinical trials.
Nevertheless, response to treatment improves survival also in
patients with initially elevated hs-cTnT, emphasizing the useful-
ness of treating also subjects with advanced cardiac damage using
rapidly effective agents.
The role of measurement of cardiac biomarkers in the
evaluation of response to treatment
Progression of cardiac biomarkers, defined as a more than 30% and
more than 300 ng/L increase of NT-proBNP, and a more than 75%
increase in hs-cTnT emerges as an important independent prognos-
tic factor in AL amyloidosis. Hematologic response is of no benefit
to patients in whom cardiac dysfunction (ie, NT-proBNP) progresses,
indicating that the impact on survival of the reduction of the
amyloidogenic light chain is dependent on its ability to induce
cardiac response or at least to prevent cardiac progression. Thus, in
AL amyloidosis, treatment efficacy should be monitored with
cardiac biomarkers (NT-proBNP and hs-cTnT). The short-term aim
of therapy should be to prevent an increase of NT-proBNP and/or
hs-cTnT, whereas inducing a NT-proBNP response can confer
additional benefit. In the presence of an elevation of NT-proBNP
and/or hs-cTnT compared with baseline, the therapeutic decision
should take into account the hematologic response: if the patient is
refractory, a different therapeutic approach should be considered.
Conversely, if a partial hematologic response has been attained, the
possibility of continuing treatment to achieve a more pronounced
reduction of amyloidogenic FLC with the aim of arresting cardiac
progression should be considered. Ideally, the biomarkers should
be monitored in parallel with the monitoring of the hematologic
response. It has recently been observed that patients with AL
amyloidosis treated with immunomodulatory drugs (IMiDs), such
as thalidomide and lenalidomide, present an increase in NT-proBNP
and cTnI that is probably treatment related. This increase in cardiac
biomarkers was reported to be asymptomatic, and its mechanisms
and prognostic impact have not been elucidated yet.20,21 However,
early reports indicate that the effect of IMiDs appears as early as
after the first cycle. Thus, frequent (eg, monthly) measurements of
cardiac biomarkers may allow identification of a direct treatment
effect underlying biomarker elevation. In the present series, 13% of
patients were treated with thalidomide and none received lenalido-
mide. Excluding patients exposed to thalidomide did not change
the results, but small numbers prevented us from performing a
separate analysis in subjects who received this drug. Thus, caution
should be used in interpreting biomarker progression in patients
who are being treated with IMiDs. Validation studies in patient
populations exposed to different types of treatments and, in
particular, in subjects who receive IMiDs are warranted.
Additional caution should be used in the presence of other
factors not related to amyloidosis or chemotherapy, for example,
fluid overload, dehydration, or concomitant nonamyloid cardiac
diseases, which may influence the concentration of cardiac biomar-
kers. The measurement of cardiac biomarkers, both at baseline and
Figure 3. Survival from the time of evaluation of response of 113 patients with
baseline NT-proBNP more than or equal to 650 ng/L according to NT-proBNP
response and progression.
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during the follow-up, should be done in a “steady state,” when
optimal control of fluid retention has been achieved by supportive
measures and in the absence of other concurrent conditions (such as
the onset of atrial fibrillation) that may affect the concentration of
cardiac biomarkers.
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